Advertisement
Canada markets open in 7 hours 1 minute

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7308
    +0.0010 (+0.14%)
     

  • CRUDE OIL

    82.98
    +0.17 (+0.21%)
     

  • Bitcoin CAD

    87,974.38
    -3,198.61 (-3.51%)
     

  • CMC Crypto 200

    1,391.30
    +8.73 (+0.63%)
     

  • GOLD FUTURES

    2,330.40
    -8.00 (-0.34%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,432.50
    -232.00 (-1.31%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     

Roche's MabTherea shot gets EU OK for chronic lymphocytic leukemia

Reuters
Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann (Reuters)

ZURICH (Reuters) - Drugmaker Roche has received European approval for an injectable form of antibody therapy MabThera for people with chronic lymphocytic leukemia, the company said on Tuesday. The European Commission approved the injection for people with previously untreated and relapsed/refractory forms of the disease. "MabThera SC provides patients with significantly faster treatment administration and the opportunity to enjoy more time outside the clinical setting compared to intravenous delivery of the medicine," Chief Medical Officer Sandra Horning said. (Reporting by Brenna Hughes Neghaiwi; Editing by Michael Shields)